药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Ranibizumab
Eluxadoline
The serum concentration of Eluxadoline can be increased when it is combined with Pitavastatin.
Ranibizumab
Cholestyramine
Cholestyramine can cause a decrease in the absorption of Pitavastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ranibizumab
Danazol
The serum concentration of Pitavastatin can be increased when it is combined with Danazol.
Ranibizumab
Trabectedin
The risk or severity of myopathy and rhabdomyolysis can be increased when Pitavastatin is combined with Trabectedin.
Ranibizumab
Raltegravir
The risk or severity of myopathy and rhabdomyolysis can be increased when Raltegravir is combined with Pitavastatin.
Ranibizumab
Ciprofibrate
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofibrate is combined with Pitavastatin.
Ranibizumab
Acipimox
Acipimox may increase the myopathic rhabdomyolysis activities of Pitavastatin.
Ranibizumab
Pralsetinib
Pralsetinib may decrease the excretion rate of Pitavastatin which could result in a higher serum level.
Ranibizumab
Valinomycin
Valinomycin may decrease the excretion rate of Pitavastatin which could result in a higher serum level.
Ranibizumab
Letermovir
Letermovir may decrease the excretion rate of Pitavastatin which could result in a higher serum level.
Ranibizumab
Lenvatinib
Lenvatinib may decrease the excretion rate of Pitavastatin which could result in a higher serum level.
Panitumumab
Aluminium phosphate
The serum concentration of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when it is combined with Aluminium phosphate.
Panitumumab
Montmorillonite
The serum concentration of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when it is combined with Montmorillonite.
Panitumumab
Aloglutamol
The serum concentration of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when it is combined with Aloglutamol.
Panitumumab
Aluminium glycinate
The serum concentration of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when it is combined with Aluminium glycinate.
Panitumumab
Hydrotalcite
The serum concentration of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when it is combined with Hydrotalcite.
Panitumumab
Aluminium acetoacetate
The serum concentration of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when it is combined with Aluminium acetoacetate.
Panitumumab
Bentonite
The serum concentration of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when it is combined with Bentonite.
Panitumumab
Aluminum sulfate
The serum concentration of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when it is combined with Aluminum sulfate.
Panitumumab
Aluminum chloride
The serum concentration of cis-Diamminechlorocholylglycinateplatinum(II) can be decreased when it is combined with Aluminum chloride.